BJD Editor's Choice  by unknown
BJD EDITOR'S CHOICE
© 2013 British Association of Dermatologists www.jidonline.org 2657
from the British Journal of Dermatology
Brachioradial pruritus
Brachioradial pruritus is a poorly understood condition that 
has been relatively neglected in the medical literature. This 
study of 111 patients with brachioradial pruritus represents 
the largest series of patients with this diagnosis reported 
to date. The study was carried out at the Mayo Clinic and 
involved a retrospective review of clinical notes over a 
12-year period. This series consisted of 72% female and 
28% male patients. In those patients referred to neurolo-
gists, structural causes were rarely identified. Br J Dermatol 
2013; doi: 10.1111/bjd.12483.
Fibroblast cell therapy for recessive 
dystrophic epidermolysis bullosa
This study aimed to determine whether fibroblast cell 
therapy can improve wound healing in recessive dystro-
phic epidermolysis bullosa. Erosions were randomized 
1 : 1 to receive marginal injections of suspended fibroblasts 
or vehicle alone. The authors reported an increased ini-
tial rate of erosion healing within the first 28 days, but not 
thereafter. They concluded that further studies are needed 
to address the potential benefits of re-treatment and the 
optimal method of cell delivery. Br J Dermatol  2013; doi: 
10.1111/bjd.12599.
Fractional laser-assisted photodynamic 
therapy of actinic keratoses
Photodynamic therapy (PDT) has inferior efficacy in organ 
transplant recipients (OTRs), particularly in acral regions. 
The aim of this study was to compare the efficacy of abla-
tive fractional laser-assisted PDT with the CO2 laser alone 
in a single treatment of multiple actinic keratoses and 
wart-like lesions in OTRs. This study on 10 OTRs showed 
a significantly higher rate of complete clearance of actinic 
keratoses and wart-like lesions with ablative fractional laser-
assisted PDT than with laser monotherapy. Br J Dermatol 
2013; doi: 10.1111/bjd.12507.
BRAF and NRAS mutations in metastatic 
melanoma
This study sought to investigate the clinical significance 
of BRAF mutation in a clinic-based cohort of patients with 
metastatic melanoma. The authors studied 265 tumours 
from 224 patients. The BRAF mutation status was analysed 
in relation to clinical and histopathological characterization 
and outcome. In patients with distant metastatic melanoma, 
those receiving BRAF inhibitor therapy had a better outcome 
than those with V600E mutant and wild-type tumours who 
were not receiving a BRAF inhibitor. The authors proposed 
that BRAF is a potential biomarker for metastatic melanoma. 
Br J Dermatol  2013; doi: 10.1111/bjd.12504.
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P = 0·31
BRAF-mutant, n = 68
NRAS-mutant, n = 48
WT, n = 47
